Marker Therapeutics, Inc. · NASDAQ:MRKR
Marker Therapeutics — Investor Presentation (November 2025)
20 slides from Marker Therapeutics's investor presentation, November 2025
Slide 1: Marker Therapeutics Corporate Presentation
MARKER THERAPEUTICS CORPORATE PRESENTATION November 2025 NASDAQ: MRKR
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other th
Slide 3: Marker Therapeutics – Value Proposition
Marker Therapeutics – Value Proposition MAR-T Cell Platform MT-601 - APOLLO Study MAR-T (Multi-Antigen Recognizing T cell, formerly MT-601 in Phase 1 clinical trial has shown durable known as multiTAA) technology was developed at objective response rates in patients with lymphoma Baylor College of M
Slide 4: MAR-T Technology
MAR-T Technology 4
Slide 5: Mechanism of Action of MAR-T Cells
Mechanism of Action of MAR-T Cells Multi For Blood No Genetic Antigen & Solid Engineering Recognition Tumors PRAME WT-1 Overlapping NY-ESO-1 peptides Multi Low Risk Intra- & Expansion Survivin Epitope for CRS or Extra- Activation & Infusion TCR Apoptosis Recognition ICANS Cellular TRAIL SSX2 Targets
Slide 6: MAR-T Cells are Generated in a Simple Manufacturing Process
MAR-T Cells are Generated in a Simple Manufacturing Process • No genetic engineering • Natural T cell expansion • Uninterrupted cell expansion • Reproducible process • Cost-effective process PBMC, peripheral blood mononuclear cells. 6
Slide 7: MAR-T Pipeline for Hematologic Malignancies and Solid Tumors
MAR-T Pipeline for Hematologic Malignancies and Solid Tumors PROGRAM / INDICATION PRECLINICAL IND PHASE 1 PHASE 2 HEMATOLOGIC MALIGNANCIES MT-601 1 (APOLLO) Lymphoma – Autologous MT-401-OTS 2 AML – Allogenic Off-the-Shelf (OTS) SOLID TUMORS MT-601 1 Pancreatic Cancer – Autologous AML, Acute Myeloid
Slide 8: MT-601 – APOLLO Study
MT-601 – APOLLO STUDY MAR-Ts targeting 6 tumor antigens for patients with lymphoma who relapsed after anti-CD19 CAR-T cells or where CAR-T cell therapy is not an option 8
Slide 9: APOLLO Study Utilizes an Optimized MAR-T Cell Product
APOLLO Study Utilizes an Optimized MAR-T Cell Product BAYLOR STUDY (1) MARKER’S MT-601 STUDY (APOLLO) • MAR-T cell product targeted 5 tumor • MAR-T cell product targets 6 tumor antigens antigens for broader target specificity • Demonstrated durable responses for up • Higher Cell Dose: 200x106 – 400x
Slide 10: Marker MT-601 APOLLO Clinical Trial Design
Marker MT-601 APOLLO Clinical Trial Design STUDY DESIGN MT-601 Dose Escalation 100-400 x 106 cells Enroll different histopathologies N=24 (e.g. DLBCL, FL, MZL, MCL, HL) MT-601 Dose Expansion Histopathology-specific Disease-specific cohort (DLBCL) (DLBCL – CAR-T and/or Start June 17, 2025 Bispecific
Slide 11: MT-601 Shows Early Objective Responses in Participants with NHL
MT-601 Shows Early Objective Responses in Participants with Non-Hodgkin Lymphoma (NHL) Response Rates* Objective Responses in Patients Who Have 100 N = 12 Complete Response Been Heavily Pre-Treated Partial Response Pre-Infusion After MT-601 Infusion 80 Percentage (%) Progressive Disease 60 40 ORR=66
Slide 12: Patients Treated in Phase 1 APOLLO Trial – Non-Hodgkin Lymphoma
Patients Treated in Phase 1 APOLLO Trial – Non-Hodgkin Lymphoma 007-601 1 LBCL 007-603 2 tFL/LBCL 007-604 3 ǂ tFL/LBCL Treated Patients Treated 009-603 9 MZL 008-601 11 FL 009-601 6 LBCL ǂ x 010-601 8 Patients MCL • ORR=8/12 (66%); CRR=6/12 (50%) 010-602 14 LBCL • 5 participants showed ≥6 months 004
Slide 13: Study Participants with NHL show Early Objective Responses
Study Participants with NHL show Early Objective Responses Patient Dose Disease CAR-T Bispecific Best LD ID Level Histology Therapy Antibodies Response 1 No 200x106 LBCL Yes No CR 2 No 200x106 tFL/LBCL Yes Yes CR 3 No/Yes 200x106 tFL/LBCL No No CR 9 Yes 200x106 MZL No No CR 11 Yes 200x106 FL Yes Yes
Slide 14: Study Participants with HL show Early Objective Responses
Study Participants with HL show Early Objective Responses Baseline D 60 Scan Response Rates N=9 100 80 Percentage (%) 60 ORR=78% 40 CRR=11% 20 0 Best Response Progressive Disease Partial Response Complete Response Study participant diagnosed with HL had 8 prior lines of treatment. Study participant
Slide 15: MT-601 Appears Safe and Well Tolerated
MT-601 Appears Safe and Well Tolerated No Dose Limiting Toxicities (DLTs) reported (doses tested ranged from 100x106 to 400x106 cells) Two Grade 1 CRS events reported (fever; no treatment required) No ICANS reported Long term toxicities currently being assessed Data as of June 2025 CRS, Cytokine Rel
Slide 16: Relapsed Lymphoma is a Large, Growing Market Opportunity
Relapsed Lymphoma is a Large, Growing Market Opportunity Post-CD19 CAR-T Could be a Multi-Billion Dollar Market Global Market • Autologous CD19 CAR-Ts have become a standard of care Potential for MT-601 in R/R NHL, generating global revenues of $3.1B in 2024 4 (26% y/y growth) Revenue (Billion USD)
Slide 17: Future Developments
Future Developments 17
Slide 18: MT-401-OTS & MT-601 – Advancing Allogeneic and Solid Tumor Programs
MT-401-OTS & MT-601 – Advancing Allogeneic and Solid Tumor Programs MT-401 Off-the-Shelf MT-601 in Pancreatic Cancer • Manufactured from healthy donors; Marker has • FDA has granted an IND to investigate MT-601 cellular inventory with plans to expand in patients with metastatic pancreatic cancer in
Slide 19: Key Takeaways
Key Takeaways In contrast to single antigen-targeting T cell therapies, MAR-Ts target multiple epitopes within up to 6 tumor-specific antigens, thereby reducing the possibility of tumor escape MAR-Ts do not require genetic engineering APOLLO study highlights: • Favorable safety profile. MT-601 was w
Slide 20: Thank You
THANK YOU 2% MARKER
Marker Therapeutics — Investor Presentation (November 2025) on 6ix